Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA4 | P48058 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | PER2 | O15055 | 1/20 | 0.30 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.30 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12203090 | 0.76 | GRIA4 (0.43) | GRIA4PER2CRY1CRY2 | |
| SCHEMBL12898950 | 0.74 | GRIA4 (0.46) | GRIA4PER2CRY1CRY2 | |
| SCHEMBL4119954 | 0.73 | GRIA4 (0.41) | GRIA4PER2CRY1CRY2 | |
| SCHEMBL12884417 | 0.73 | GRIA4 (0.44) | GRIA4PER2CRY1CRY2 | |
| SCHEMBL8282273 | 0.71 | GRIA4 (0.40) | GRIA4 | |
| SCHEMBL13690769 | 0.71 | GRIA4 (0.40) | GRIA4 | |
| SCHEMBL8270968 | 0.70 | GRIA4 (0.39) | GRIA4 | |
| SCHEMBL22457461 | 0.69 | GRIA4 (0.40) | GRIA4PER2CRY1CRY2 | |
| SCHEMBL8280603 | 0.68 | GRIA4 (0.38) | GRIA4 | |
| SCHEMBL91255 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431565-B2 | Substituted imidazoheterocycles | CARA THERAPEUTICS, INC. (US) | 2013-04-30 | — | — | US | claimed |
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-06-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CNR1, CNR2, TRPV1 | GRIA4 557/4885POLB 3552/4885PER2 1612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.